IOL Chemicals & Pharmaceuticals Ltd Q1 FY27 Earnings Analysis

- The company targets mid-teen annual revenue growth, around 15%, for FY 2027 and the next few years. - They expect to achieve revenues of approximately INR 2,700 crores in FY 2027 based on current capacity and growth plans. - Maximum revenue potential from existing capacities is estimated at INR 3,200 to INR 3,300 crores. - Growth is driven by capacity utilization improvements, e.g., paracetamol plant expected to ramp from 55% to 75% or higher in FY 2027, and full capacity by FY 2028. - Export share, especially for non-ibuprofen products, is targeted to increase to about 25% in FY 2027, with existing 40-50% exports in ibuprofen growing further. - The new greenfield project will undergo phased capex (~INR 200-250 crores annually) aiming for INR 1,200-1,400 crores total over 4-5 years, supporting future growth. - Overall, they anticipate annualized growth in the mid to high teens range in sales and volumes over the medium term.

- The company expects mid-teen to high-teen revenue growth over the medium term (~15%-18%). - For FY 2027, guidance includes mid-teen revenue growth and EBITDA margin of around 14% to 14.5%. - PAT is expected to grow in line with revenue, with improvements in EBITDA margins supporting earnings. - Management emphasizes gauging performance on a yearly basis rather than quarterly due to global dynamism. - Growth drivers include increased capacity utilization, higher contribution from non-Ibuprofen products, and operational efficiencies. - Capex for greenfield projects planned at around INR 1,200 to 1,400 crores over 4-5 years, with phased investments of INR 200-250 crores annually. - No significant margin pressure expected in Ibuprofen; capacity utilization stays high (~90%-95%). - Overall, sustainable improvement in profitability and EPS anticipated through better product mix and pricing aligned with raw material costs.

- IOL Chemicals has acquired 100 acres of land near Bhatinda Highway for a new greenfield project. - The project is expected to commence in the next 4 to 6 quarters, with most regulatory approvals in progress, including environmental clearance already secured. - The total capex for this new site is estimated between INR 1,200 crores to INR 1,400 crores. - Capex will be executed in a phased manner over 4 to 5 years, with annual investments of around INR 200 to 250 crores. - The greenfield plant will have a similar model to the existing one, focusing on a mix of chemical and API products. - Current year capex is around INR 200 crores, split approximately 60% for growth projects and 40% for infrastructure and efficiency improvements. - No major capex initiated yet at the new greenfield site beyond initial boundary and infrastructure development.

- As of the conference call on May 22, 2026, IOL Chemicals and Pharmaceuticals Limited has not discussed any buyback or equity fundraising plans. - The management stated there is no current buyback consideration, as focus is on growth; buyback may be considered only after growth projects are funded. - Regarding capital expenditure, the company plans significant capex (INR 1,200 to 1,400 crores) over the next 4-5 years for a new greenfield project, to be funded via internal accruals. - Annual capex of INR 200-250 crores is expected, gradually and phased, without mention of external debt or equity raising. - No mention of new debt fundraising was made during the call. - Overall, current strategy is to fund growth and capex internally, without immediate plans for external debt or equity fundraising.

The transcript does not explicitly mention current or expected order book or pending orders for IOL Chemicals and Pharmaceuticals Limited. However, some relevant points that provide insight into demand and growth expectations are: - Company expects mid to high-teen revenue growth for FY 2027, indicating a healthy order pipeline. - Capacity utilization is strong: Ibuprofen at ~90-95%, other products at 85-95%, paracetamol increasing from 55% to 75%. - Demand for ibuprofen has stabilized and is expected to maintain for next 4-6 quarters. - Export share, especially in non-ibuprofen products, is growing, with European market expansion expected. - New greenfield project underway with phased capex of INR 200-250 crores annually over 4-5 years to support growth. - No direct data on order book size or pending orders was disclosed. In summary, the company signals good demand visibility and capacity utilization but does not provide specific order book or pending order numbers.